Literature DB >> 34463727

Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction.

Dan Haberman1, Rodrigo Estévez-Loureiro2, Tomas Benito-Gonzalez3, Paolo Denti4, Dabit Arzamendi5, Marianna Adamo6, Xavier Freixa7, Luis Nombela-Franco8, Pedro Villablanca9, Lian Krivoshei10, Neil Fam11, Konstantinos Spargias12, Andrew Czarnecki13, Isaac Pascual14, Fabien Praz15, Doron Sudarsky16, Arthur Kerner17, Vlasis Ninios18, Marco Gennari19,20, Ronen Beeri21, Leor Perl22, Yishay Wasserstrum23, Haim Danenberg21, Lion Poles1, Jacob George1, Berenice Caneiro-Queija2, Salvatore Scianna20, Igal Moaraf24, Davide Schiavi4, Claudia Scardino25, Noé Corpataux15, Julio Echarte-Morales3, Michael Chrissoheris12, Estefanía Fernández-Peregrina5, Mattia Di Pasquale6, Ander Regueiro7, Carlos Vergara-Uzcategui8, Andres Iñiguez-Romo2, Felipe Fernández-Vázquez3, Danny Dvir26, Francesco Maisano4, Maurizio Taramasso20, Mony Shuvy21,26.   

Abstract

AIMS: Severe mitral regurgitation (MR) following acute myocardial infarction (MI) is associated with high mortality rates and has inconclusive recommendations in clinical guidelines. We aimed to report the international experience of patients with secondary MR following acute MI and compare the outcomes of those treated conservatively, surgically, and percutaneously. METHODS AND
RESULTS: Retrospective international registry of consecutive patients with at least moderate-to-severe MR following MI treated in 21 centres in North America, Europe, and the Middle East. The registry included patients treated conservatively and those having surgical mitral valve repair or replacement (SMVR) or percutaneous mitral valve repair (PMVR) using edge-to-edge repair. The primary endpoint was in-hospital mortality. A total of 471 patients were included (43% female, age 73 ± 11 years): 205 underwent interventions, of whom 106 were SMVR and 99 PMVR. Patients who underwent mitral valve intervention were in a worse clinical state (Killip class ≥3 in 60% vs. 43%, P < 0.01), but yet had lower in-hospital and 1-year mortality compared with those treated conservatively [11% vs. 27%, P < 0.01 and 16% vs. 35%, P < 0.01; adjusted hazard ratio (HR) 0.28, 95% confidence interval (CI) 0.18-0.46, P < 0.01]. Surgical mitral valve repair or replacement was performed earlier than PMVR [median of 12 days from MI date (interquartile range 5-19) vs. 19 days (10-40), P < 0.01]. The immediate procedural success did not differ between SMVR and PMVR (92% vs. 93%, P = 0.53). However, in-hospital and 1-year mortality rates were significantly higher in SMVR than in PMVR (16% vs. 6%, P = 0.03 and 31% vs. 17%, P = 0.04; adjusted HR 3.75, 95% CI 1.55-9.07, P < 0.01).
CONCLUSIONS: Early intervention may mitigate the poor prognosis associated with conservative therapy in patients with post-MI MR. Percutaneous mitral valve repair can serve as an alternative for surgery in reducing MR for high-risk patients. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Mitral regurgitation; Mitral valve surgery; Myocardial infarction; Percutaneous edge-to-edge repair

Mesh:

Year:  2022        PMID: 34463727     DOI: 10.1093/eurheartj/ehab496

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

1.  FGF6 promotes cardiac repair after myocardial infarction by inhibiting the Hippo pathway.

Authors:  Zhicheng Hu; Peng Chen; Linlin Wang; Yu Zhu; Gen Chen; Yunjie Chen; Zhenyu Hu; Lin Mei; Weijing You; Weitao Cong; Litai Jin; Xu Wang; Yang Wang; Xueqiang Guan
Journal:  Cell Prolif       Date:  2022-03-30       Impact factor: 8.755

2.  Trends in Ischemic Mitral Regurgitation Following ST-Elevation Myocardial Infarction Over a 20-Year Period.

Authors:  Leor Perl; Tamir Bental; Katia Orvin; Hana Vaknin-Assa; Gabriel Greenberg; Pablo Codner; Yaron Shapira; Mordehay Vaturi; Alexander Sagie; Ran Kornowski
Journal:  Front Cardiovasc Med       Date:  2022-01-13

3.  A Hybrid Intervention for Post-infarction Papillary Muscle Rupture with Severe Mitral Regurgitation: A Case Report.

Authors:  Kosuke Nakamae; Takashi Oshitomi; Hideyuki Uesugi
Journal:  J Chest Surg       Date:  2022-06-05

Review 4.  Mechanical Circulatory Support Devices for the Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction-A Review.

Authors:  Sharon Bruoha; Chaim Yosefy; Louay Taha; Danny Dvir; Mony Shuvy; Rami Jubeh; Shemy Carasso; Michael Glikson; Elad Asher
Journal:  J Clin Med       Date:  2022-09-05       Impact factor: 4.964

Review 5.  Percutaneous mitral valve repair in patients developing severe mitral regurgitation early after an acute myocardial infarction: A review.

Authors:  Rodrigo Estévez-Loureiro; Marta Tavares Da Silva; José Antonio Baz-Alonso; Berenice Caneiro-Queija; Manuel Barreiro-Pérez; Francisco Calvo-Iglesias; Rocio González-Ferreiro; Luis Puga; Miguel Piñón; Andrés Íñiguez-Romo
Journal:  Front Cardiovasc Med       Date:  2022-09-23

Review 6.  Acute Ischaemic Mitral Valve Regurgitation.

Authors:  Breda Hennessey; Nestor Sabatovicz; Maria Del Trigo
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

7.  Percutaneous Mitral Valve Repair in Patients with Severe Mitral Regurgitation and Acute Decompensated Heart Failure.

Authors:  Anna Turyan Medvedovsky; Dan Haberman; Mahsati Ibrahimli; Ivaylo Tonchev; Yonatan Rashi; Alona Peretz; Sara Shimoni; Ortal Tuvali; Haim Danenberg; Ronen Beeri; Mony Shuvy
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.